Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy. Pediatr Dermatol 2021 Jan;38(1):18-30
Date
12/31/2020Pubmed ID
33378085DOI
10.1111/pde.14495Scopus ID
2-s2.0-85098284468 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
Cancer remains a leading cause of morbidity and mortality among children. Targeted therapies may improve survivorship; however, unique side-effect profiles have also emerged with these novel therapies. Changes in hair, skin, and nails-termed dermatologic adverse events (AEs)-are among the most common sequelae and may result in interruption or discontinuation of therapy. Though dermatologic AEs have been detailed in adults, these findings are not well described in the pediatric population. We reviewed the literature to characterize dermatologic AEs to anticancer targeted therapies available as of July 2020 and summarized the spectrum of clinical findings as well as treatment recommendations for children. Dermatologic AEs are among the most common AEs reported in pediatric patients receiving targeted therapy, but morphologic and histologic descriptions are often lacking in current publications. Pediatric dermatologists are uniquely poised to recognize specific morphology of dermatologic AEs and make recommendations for prevention and treatment that may improve quality of life and enable ongoing cancer therapy.
Author List
Carlberg VM, Davies OMT, Brandling-Bennett HA, Leary SES, Huang JT, Coughlin CC, Gupta DAuthor
Valerie M. Carlberg MD Associate Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsChild
Humans
Molecular Targeted Therapy
Neoplasms
Quality of Life
Skin
